pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-4697 |
Genomic Coordinates | chr11: 133898504 - 133898581 |
Description | Homo sapiens miR-4697 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-4697-5p | |||||||||||||||||||||
Sequence | 10| AGGGGGCGCAGUCACUGACGUG |31 | |||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||
Experiments | Illumina | |||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | QSOX2 | ||||||||||||||||||||
Synonyms | QSCN6L1, SOXN | ||||||||||||||||||||
Description | quiescin sulfhydryl oxidase 2 | ||||||||||||||||||||
Transcript | NM_181701 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on QSOX2 | |||||||||||||||||||||
3'UTR of QSOX2 (miRNA target sites are highlighted) |
>QSOX2|NM_181701|3'UTR 1 GTGCCCGGGTGCTGCCAGCCACGGCGGAAGCTCCCTTGGAGGCAGCCCTGCCCCGTGCCACCTGCAGCTTTAATATTTAT 81 GATCAGGGATTTTATAAACATGCGGGCCTGGTTTCACATCGGATGGCACCTTTTGGCTTCAAAGTCCTGGTTTTACAAAC 161 GCTCTTCTAACAAGGGAAGAACACGGGGTAATTTTGTGGGGATATTTGCATTCCTGGCGTACTCAAGTCTGTTCATGCTC 241 CTTTTGCAGGTCTTACAGCAAAAAGACTTCTGTATTTTTACTCTTCTAGATGTGAAAAGAGGGTGCAGAGTCCAGGCCAG 321 ATAGTCTTCCCCACACACTTTCATCTCGTTTCCTCCACTCCGCCCCATCCTGCAGGGCCTTGTTTTTGTATTTGGAGAAC 401 CTCGCCCATCCCCCCCGCGGCTCCTGGCTCCCCCCCACTCCCCTCGCTCCCCCTCCCCCCGCTCCCCCCACGCCCCCTGC 481 TCCAGGCTGCCAAGTGTTTTCCTTTAGCCGGGCGGGGACAGACAGAGCCGGAAGCGCAGTCGGCCTCTGCAGCCCCTCCA 561 AGCAAGTGCTCCAGGGACTATCCTGTGTTTGTAGCTGCTTCCCTAGGGCAGGTTCCTGAGGGCTCTCCTTGTTCCTCCGG 641 GTGTTCGACACCAGACGTGGGGATTTCAACAGGGGAGGAGCCAAGGAATTCTGTGGCTGTGCTGCGTTTCAGAAAATAAC 721 CCCCAGAGGCCTTGGGCTGTGGACCTGGGGGTTGGAAGGATGGGGGCTCATTTAACCCTCAGAGGCAGCGCCTTTGTCTG 801 TCTATCTGGTGACAAGAGAGAGACAAGTAAATGGGGGCCGTTGGGACGGCGGGTGCCTGGAGGGCAGCTCTGGGCTCAGC 881 GGGCAGTGCTTAGAGCACAGGCCCCTCTGTTGGGGGATGGGGAGGAGAGCAGTCTGCCCTTGGGAGCGTAGGCCCCAGGG 961 AGACTTCTAAAGCCCCCCCTGTCGTCTGCTCTTCACCCAGCACCACAGAGGCACCTGCTGCACACACAAGCATCTCACTC 1041 GGCCCACGGAGGGGGCCAGGCTTCCTTTGCCTGAAGCTGTTTTGGGAAGGGTCTCCACACAGGCACTGATCTCCCAAGCT 1121 TTTGTCATGATGTCTTTTACCATTTGATAATTTTAAACATTGTTTTTAAACCCAAAACATTTAGTGGTCCGTTGCCTCTG 1201 AAGATGTAAACAAACAAATACACTATTTCTGGGAACATTTATATTGAGATTCTTTGTGGCTATTGGTGTGTCTCACAGGC 1281 AAAATTTGATTTGGCTAAAATAGGCTCAGATGTATTTGTGTGCCCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1361 TGTATGAGAGAGAGAGAGACTTTGACGGTTGTAGATATTTTTTCCGCTTTGCCTACTTTATGTTGTATAATCATGTGTTT 1441 ACTAACAAGTTGATGACATGGATGTATTCATAAGACCATGTAATATTGATGTGATTGTTGTCGCTTGAGAAAAAAAGGCA 1521 ACAGCTGATTCTTTCAACAACTGTCACAGAATGGCTGGGCTGAGAACGCTGCCCAGGGCCCTGCAGCTGGCGGGAGAGGT 1601 GTCTGGTGGGAGCGGTGTCTGGTGCGTCAGCCTGCTGCTTCGTGTCTCACTCGAGAGTTGCTTCTGGTTTCACACTTTTT 1681 AACCCCTCTGTGCTTTAGCAGCCGTGACCTTGCCTTCATTGCTTCATCCAGTGCAGGCCTGGGTTATTGAAGACACCAAA 1761 GTGTTTCTCTTCCAGTTTGAAAACCAGGCAGGTTTACACGTGGGTTTCAGTGTATTTGCCTTTGAACCCTTCAAACTAAA 1841 CTTTAGCCTTTTGGCTGGTGTTGAATGTCTTTAGCTGGGGTGACCTGGAGTGACCTGGGACGGTGTTGTGGTTTACCGTC 1921 TCCAGCTTCAGCCTTTCCAGAAACCCTTGTGGAGGGCAGTGTTGGCTGCAGGTTTCATCATATTGCAGTTTGAGGTCACC 2001 ACTATTTGGGGAACAAGCTTGCGTCCTGCTGAGGGGCAGGATTTTCAGCAGAGCGTCGGTGGGGCTGGGCCGTCGTGGAG 2081 GTGGCCCCAGGAGTCATATGGCCATACTCAGACACACCTTGTGTGGCCTGCTCAGAGCTGGATGCCACCTTTAGGCAATG 2161 TTTAGAGTCTATTTTCTAAAGTTTTAAGTATTTTAAGAGGTATTGAGACTAATGAATATAATAGTTCAGTAATTTAAATG 2241 CTTATTTATTTTCAGTGGAAGGATTTTTATTAAAAAGAAGCTAATTGACATGGAAATGTCAGTGAAATTTCTTACCTGCA 2321 AGGAAAGTGAACATTTTGTATTTAAGTAAACTATAATGTGCACATTTTAATAAAGAAATCTGACATTTGAAAAAAAAAAA 2401 AAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
miRNA:Target | ---- | |||||||||
Validation Method |
|
|||||||||
Conditions | HEK293 | |||||||||
Location of target site | 3'UTR | |||||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | |||||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545215. RNA binding protein: AGO4. Condition:Control
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
|||||||||
miRNA-target interactions (Provided by authors) |
|
|||||||||
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | C8166 , TZM-bl |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462572. RNA binding protein: AGO2. Condition:C8166 NL4-3
PAR-CLIP data was present in GSM1462573. RNA binding protein: AGO2. Condition:TZM-bl BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HCT116 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in ERX177614. RNA binding protein: AGO2. Condition:KO_V_AGO_CLIP_3_4
PAR-CLIP data was present in ERX177623. RNA binding protein: AGO2. Condition:p53_D_AGO_CLIP_4_1
PAR-CLIP data was present in ERX177618. RNA binding protein: AGO2. Condition:KO_V_AGO_CLIP_3_8
PAR-CLIP data was present in ERX177630. RNA binding protein: AGO2. Condition:KO_V_AGO_CLIP_4_8
PAR-CLIP data was present in ERX177626. RNA binding protein: AGO2. Condition:KO_V_AGO_CLIP_4_4
PAR-CLIP data was present in ERX177605. RNA binding protein: AGO2. Condition:KO_D_AGO_CLIP_2_7
PAR-CLIP data was present in ERX177606. RNA binding protein: AGO2. Condition:KO_V_AGO_CLIP_2_8
... - Krell J; Stebbing J; Carissimi C; Dabrowska et al., 2016, Genome research. |
Article |
- Krell J; Stebbing J; Carissimi C; Dabrowska et al. - Genome research, 2016
DNA damage activates TP53-regulated surveillance mechanisms that are crucial in suppressing tumorigenesis. TP53 orchestrates these responses directly by transcriptionally modulating genes, including microRNAs (miRNAs), and by regulating miRNA biogenesis through interacting with the DROSHA complex. However, whether the association between miRNAs and AGO2 is regulated following DNA damage is not yet known. Here, we show that, following DNA damage, TP53 interacts with AGO2 to induce or reduce AGO2's association of a subset of miRNAs, including multiple let-7 family members. Furthermore, we show that specific mutations in TP53 decrease rather than increase the association of let-7 family miRNAs, reducing their activity without preventing TP53 from interacting with AGO2. This is consistent with the oncogenic properties of these mutants. Using AGO2 RIP-seq and PAR-CLIP-seq, we show that the DNA damage-induced increase in binding of let-7 family members to the RISC complex is functional. We unambiguously determine the global miRNA-mRNA interaction networks involved in the DNA damage response, validating them through the identification of miRNA-target chimeras formed by endogenous ligation reactions. We find that the target complementary region of the let-7 seed tends to have highly fixed positions and more variable ones. Additionally, we observe that miRNAs, whose cellular abundance or differential association with AGO2 is regulated by TP53, are involved in an intricate network of regulatory feedback and feedforward circuits. TP53-mediated regulation of AGO2-miRNA interaction represents a new mechanism of miRNA regulation in carcinogenesis.
LinkOut: [PMID: 26701625]
|
CLIP-seq Support 1 for dataset GSM4903838 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / 124_TD_21_c |
Location of target site | NM_181701 | 3UTR | CCUGCUCCAGGCUGC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM545215 | |
---|---|
Method / RBP | PAR-CLIP / AGO4 |
Cell line / Condition | HEK293 / Control |
Location of target site | ENST00000358701.5 | 3UTR | CUCCCCUCGCUCCCCCUCCCCCCGCUCCCCCCACGCC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 3 for dataset GSM1462572 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | C8166 / C8166 NL4-3 |
Location of target site | ENST00000358701.5 | 3UTR | CUCCCCUCGCUCCCCCUCCCCCCGCUCCCCCCACGCCCC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
CLIP-seq Support 4 for dataset GSM1462573 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | TZM-bl / TZM-bl BaL |
Location of target site | ENST00000358701.5 | 3UTR | CACUCCCCUCGCUCCCCCUCCCCCCGCUCCCCCCACGCCC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
67 hsa-miR-4697-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT441332 | C19orf26 | CACN beta subunit associated regulatory protein | 2 | 4 | ||||||||
MIRT451390 | FARSA | phenylalanyl-tRNA synthetase alpha subunit | 2 | 2 | ||||||||
MIRT452310 | EIF5AL1 | eukaryotic translation initiation factor 5A-like 1 | 2 | 2 | ||||||||
MIRT455043 | MEN1 | menin 1 | 2 | 2 | ||||||||
MIRT455256 | DDX39B | DExD-box helicase 39B | 2 | 10 | ||||||||
MIRT461279 | COX10 | COX10, heme A:farnesyltransferase cytochrome c oxidase assembly factor | 2 | 2 | ||||||||
MIRT464945 | TXLNA | taxilin alpha | 2 | 4 | ||||||||
MIRT468043 | SIK1 | salt inducible kinase 1 | 2 | 2 | ||||||||
MIRT472523 | NACC1 | nucleus accumbens associated 1 | 2 | 2 | ||||||||
MIRT472929 | MSN | moesin | 2 | 2 | ||||||||
MIRT473247 | MIDN | midnolin | 2 | 2 | ||||||||
MIRT475828 | HDGF | heparin binding growth factor | 2 | 2 | ||||||||
MIRT478744 | CS | citrate synthase | 2 | 2 | ||||||||
MIRT480081 | CALR | calreticulin | 2 | 2 | ||||||||
MIRT483482 | STMN3 | stathmin 3 | 2 | 4 | ||||||||
MIRT483643 | QSOX2 | quiescin sulfhydryl oxidase 2 | 2 | 4 | ||||||||
MIRT483721 | THSD4 | thrombospondin type 1 domain containing 4 | 2 | 2 | ||||||||
MIRT484539 | BARHL1 | BarH like homeobox 1 | 2 | 6 | ||||||||
MIRT486041 | WSCD1 | WSC domain containing 1 | 2 | 4 | ||||||||
MIRT486142 | SIX5 | SIX homeobox 5 | 2 | 6 | ||||||||
MIRT486498 | MYH11 | myosin heavy chain 11 | 2 | 2 | ||||||||
MIRT486977 | STEAP3 | STEAP3 metalloreductase | 2 | 4 | ||||||||
MIRT487279 | AGPAT6 | glycerol-3-phosphate acyltransferase 4 | 2 | 4 | ||||||||
MIRT487742 | MIB2 | mindbomb E3 ubiquitin protein ligase 2 | 2 | 2 | ||||||||
MIRT487987 | RXRB | retinoid X receptor beta | 2 | 2 | ||||||||
MIRT488338 | PAX2 | paired box 2 | 2 | 2 | ||||||||
MIRT488668 | WWP2 | WW domain containing E3 ubiquitin protein ligase 2 | 2 | 4 | ||||||||
MIRT488752 | FXYD1 | FXYD domain containing ion transport regulator 1 | 2 | 2 | ||||||||
MIRT488812 | TBC1D28 | TBC1 domain family member 28 | 2 | 2 | ||||||||
MIRT489380 | RAB11B | RAB11B, member RAS oncogene family | 2 | 2 | ||||||||
MIRT489744 | TACC3 | transforming acidic coiled-coil containing protein 3 | 2 | 2 | ||||||||
MIRT489960 | GNB2 | G protein subunit beta 2 | 2 | 2 | ||||||||
MIRT490418 | VPS51 | VPS51, GARP complex subunit | 2 | 4 | ||||||||
MIRT490639 | FEM1A | fem-1 homolog A | 2 | 2 | ||||||||
MIRT491086 | MSI1 | musashi RNA binding protein 1 | 2 | 4 | ||||||||
MIRT491298 | VGF | VGF nerve growth factor inducible | 2 | 4 | ||||||||
MIRT491366 | SLC12A5 | solute carrier family 12 member 5 | 2 | 2 | ||||||||
MIRT492464 | RASD1 | ras related dexamethasone induced 1 | 2 | 4 | ||||||||
MIRT492872 | NFIX | nuclear factor I X | 2 | 2 | ||||||||
MIRT492951 | NEUROD2 | neuronal differentiation 2 | 2 | 2 | ||||||||
MIRT493704 | H2AFX | H2A histone family member X | 2 | 2 | ||||||||
MIRT493977 | EIF1 | eukaryotic translation initiation factor 1 | 2 | 4 | ||||||||
MIRT500360 | ZNF385A | zinc finger protein 385A | 2 | 2 | ||||||||
MIRT501154 | SLC10A7 | solute carrier family 10 member 7 | 2 | 6 | ||||||||
MIRT509625 | RRP7A | ribosomal RNA processing 7 homolog A | 2 | 4 | ||||||||
MIRT512232 | ATG2A | autophagy related 2A | 2 | 8 | ||||||||
MIRT529822 | ARGFX | arginine-fifty homeobox | 2 | 4 | ||||||||
MIRT531179 | SIGLEC12 | sialic acid binding Ig like lectin 12 (gene/pseudogene) | 2 | 2 | ||||||||
MIRT538971 | BCL7A | BCL tumor suppressor 7A | 2 | 2 | ||||||||
MIRT548357 | ENTPD5 | ectonucleoside triphosphate diphosphohydrolase 5 | 2 | 4 | ||||||||
MIRT553634 | TJAP1 | tight junction associated protein 1 | 2 | 2 | ||||||||
MIRT558050 | EVI5L | ecotropic viral integration site 5 like | 2 | 2 | ||||||||
MIRT562548 | CCDC71L | coiled-coil domain containing 71 like | 2 | 4 | ||||||||
MIRT568941 | RUNX3 | runt related transcription factor 3 | 2 | 2 | ||||||||
MIRT569114 | ONECUT3 | one cut homeobox 3 | 2 | 2 | ||||||||
MIRT573591 | CERS1 | ceramide synthase 1 | 2 | 2 | ||||||||
MIRT619317 | ARHGAP18 | Rho GTPase activating protein 18 | 2 | 2 | ||||||||
MIRT621202 | ARPC1B | actin related protein 2/3 complex subunit 1B | 2 | 2 | ||||||||
MIRT628844 | FAM151B | family with sequence similarity 151 member B | 2 | 2 | ||||||||
MIRT670497 | LYRM4 | LYR motif containing 4 | 2 | 2 | ||||||||
MIRT670545 | SHISA2 | shisa family member 2 | 2 | 2 | ||||||||
MIRT671026 | PCDHB2 | protocadherin beta 2 | 2 | 2 | ||||||||
MIRT688989 | ATP6AP1 | ATPase H+ transporting accessory protein 1 | 2 | 2 | ||||||||
MIRT709275 | MAPK8IP2 | mitogen-activated protein kinase 8 interacting protein 2 | 2 | 2 | ||||||||
MIRT715084 | ELOF1 | elongation factor 1 homolog | 2 | 2 | ||||||||
MIRT718348 | NPBWR1 | neuropeptides B and W receptor 1 | 2 | 2 | ||||||||
MIRT737406 | MMP7 | matrix metallopeptidase 7 | 2 | 0 |
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|